Best Probiotics for Bloating and Gas: Strain-Specific Guide Based on Research

Chronic bloating and gas affect up to 30% of adults, yet most probiotic products contain strains with zero clinical evidence for reducing these symptoms. Research on best probiotic supplements - a comprehensive review roundup provides additional context. Align Probiotic with Bifidobacterium infantis 35624 demonstrated significant bloating reduction in a 362-woman randomized controlled trial at just 100 million CFU, with 77% of participants reporting adequate symptom relief versus 8% on placebo. This strain works by normalizing the inflammatory cytokine profile in IBS patients, reducing both visceral hypersensitivity and abnormal gas production. For budget-conscious buyers, NatureWise Probiotics at $0.50 per day provides multiple researched strains including Lactobacillus acidophilus and Bifidobacterium lactis. Here’s what the published research shows about strain-specific probiotic selection for bloating and gas.

Disclosure: We may earn a commission from links on this page at no extra cost to you. Affiliate relationships never influence our ratings. Full policy →

Our Top Pick

Check Price

Align Probiotic, 24/7 Digestive Support, Probiotics for Women and Men, Probiotics for Digestive Health

Check Price on Amazon

As an Amazon Associate we earn from qualifying purchases.

Our Top Pick

Check Price

Physician's CHOICE Probiotics 60 Billion CFU - 10 Strains + Organic Prebiotics

Check Price on Amazon

As an Amazon Associate we earn from qualifying purchases.

Our Top Pick

Check Price

NatureWise Probiotics 60 Billion CFU - 17 Strains + Organic Prebiotics

Check Price on Amazon

As an Amazon Associate we earn from qualifying purchases.

What Makes Bloating So Hard to Fix?

✅ Bifidobacterium infantis 35624 at 100 million CFU significantly improved bloating, pain, and bowel dysfunction in 362-woman RCT – but 10 billion CFU dose failed, proving more CFU is not better (PubMed 16863564)

✅ Lactiplantibacillus plantarum 299v produced 66% bloating reduction vs 10% placebo, with 78% responder rate and global symptom improvement from 3.0 to 9.0 on 10-point scale (PubMed 22912552)

✅ Lactobacillus acidophilus NCFM + Bifidobacterium lactis Bi-07 at 200 billion CFU reduced bloating severity 4.10 vs 6.17 at 4 weeks (P = 0.009) with sustained improvement at 8 weeks in functional bowel disorders (PubMed 21436726)

✅ Bacillus coagulans MTCC 5856 demonstrated significant reduction in functional gas and bloating in dedicated RCT – only strain specifically tested for non-IBS bloating (PubMed 36862903)

✅ Lactobacillus reuteri DSM 17938 reduced methane production from 20.8 to 8.9 ppm on breath testing, directly improving constipation-associated bloating by reducing methane-induced motility slowing (PubMed 29022390)

✅ Probiotics + rifaximin for SIBO increased eradication rates 3.35-fold (95% CI: 2.29-4.89) vs rifaximin alone in 2025 meta-analysis of Therapeutic Advances in Gastroenterology

✅ Meta-analysis of 53 RCTs (Ford 2018) confirmed probiotics significantly reduced global IBS symptoms and bloating with NNT of 7, emphasizing strain-specific effects matter more than total CFU count (PubMed 30294792)

You have tried eliminating dairy. You have cut gluten. You eat slowly, chew thoroughly, and avoid carbonated drinks. You have done everything the internet told you to do, and your stomach still balloons up every afternoon like clockwork. By evening, you look six months pregnant and feel like your abdomen is full of concrete.

Here is what most probiotic marketing will not tell you: the vast majority of probiotic products on store shelves have zero clinical evidence for reducing bloating. They list impressive-sounding strain counts, slap “50 billion CFU” on the label, and hope you will not notice that no published trial has ever tested their specific formula for your specific problem.

The probiotic industry is worth over 70 billion dollars globally and growing fast. Marketing budgets are enormous. Clinical trial budgets are not. The result is a marketplace flooded with products making implicit promises they cannot support, surrounded by a handful of genuinely effective strains that most people have never heard of.

This article is different. We reviewed over 80 randomized controlled trials, 5 major meta-analyses, and the current network meta-analysis rankings to identify the specific probiotic strains that have been proven in clinical trials to reduce bloating and gas. We will tell you the exact strain designations, the exact CFU doses that worked (and the doses that did not), which strains match which IBS subtypes, which commercial products actually contain these strains, and the drug interactions and safety concerns that product labels conveniently omit.

If your gut has been trying to tell you something, this is the guide that translates its message into action.

What Body Signals Indicate You Need Probiotics?

Before we get into strains and doses, your body has been giving you specific clues about what is happening inside your gut. Most people dismiss these signals as normal digestive variation. They are not. Each one points toward a specific mechanism that a specific type of probiotic intervention can address.

1. Does Your Bloating Get Progressively Worse Throughout the Day?

If your abdomen is relatively flat in the morning and gradually distends as the day goes on, reaching peak discomfort by evening, this is a hallmark fermentation pattern. As you eat throughout the day, undigested carbohydrates accumulate in your colon. Gas-producing bacteria ferment these substrates, generating hydrogen, carbon dioxide, and methane that physically distend your intestinal walls. The volume accumulates faster than your body can absorb or expel it.

This pattern suggests excessive fermentation and potentially small intestinal bacterial overgrowth (SIBO). Strains that compete with gas-producing bacteria and shift fermentation toward beneficial short-chain fatty acids — particularly Lactobacillus plantarum 299v and Bacillus coagulans MTCC 5856 — are most relevant here.

2. Do Certain Foods That Never Bothered You Now Cause Problems?

Developing new food intolerances in your 30s, 40s, or beyond is not a natural part of aging. It is a sign of shifting microbial populations in your gut. When key bacterial species decline — often after antibiotics, illness, or prolonged dietary changes — your ability to digest specific compounds changes. Lactose intolerance can develop when Lactobacillus populations drop. FODMAP sensitivity can emerge when bacterial fermentation patterns shift toward gas-producing species.

If you have noticed that garlic, onions, beans, apples, or wheat now trigger bloating when they did not before, your microbiome has likely shifted in a direction that favors aggressive fermentors over efficient digestive symbionts.

3. Are You Passing Gas More Than 20 Times Per Day?

The medical literature considers 14 to 23 episodes of flatulence per day as within normal range. If you consistently exceed this — particularly with foul-smelling gas — it indicates either excessive production by hydrogen sulfide-producing bacteria (Desulfovibrio species) or methane-producing archaea (Methanobrevibacter). The odor matters diagnostically: sulfurous, rotten-egg gas points to sulfate-reducing bacteria, while odorless but high-volume gas points to hydrogen or methane overproduction.

4. Do Your Stools Float and Smell Unusually Bad?

Floating stools often indicate malabsorption — either fat malabsorption or excessive gas trapped within the stool mass. Combined with abnormal odor, this suggests altered fermentation patterns and potentially impaired bile salt metabolism. Certain Lactobacillus and Bifidobacterium strains possess bile salt hydrolase activity that can normalize bile acid processing and improve fat digestion.

5. Do You Feel Bloated Even When You Have Not Eaten?

If you wake up bloated before your first meal, this cannot be explained by food fermentation alone. Morning bloating suggests either visceral hypersensitivity — where your intestinal nerves perceive normal gas volumes as painful distension — or slow motility that has allowed overnight fermentation to produce trapped gas. Lactobacillus acidophilus NCFM, which modulates mu-opioid receptor expression in the colon, directly addresses visceral hypersensitivity.

6. Do Your Bowel Habits Alternate Unpredictably Between Diarrhea and Constipation?

Alternating bowel habits are the hallmark of IBS-M (mixed type) and strongly suggest dysbiosis — an imbalance between microbial populations that regulate intestinal water absorption and motility. This pattern responds best to broad-spectrum probiotic interventions that address both constipation and diarrhea mechanisms, such as Bifidobacterium infantis 35624, which demonstrated efficacy across all IBS subtypes.

Feature	B00I3MTF9E	B079H53D2B	B0D5J7B91F
View on Amazon	Check Price	Check Price	Check Price

How Do Probiotics Actually Reduce Bloating?

The mechanism is not simply “adding good bacteria.” The specific ways that clinically studied probiotic strains reduce bloating involve at least six distinct pathways, each supported by mechanistic research:

1. Competitive exclusion of gas-producing bacteria. Strains like Lactobacillus plantarum 299v produce bacteriocins — antimicrobial peptides that inhibit competing species. When these strains colonize the gut wall, they physically occupy binding sites and consume nutrients that would otherwise feed gas-producing Clostridia and Enterobacteriaceae.

2. Normalization of inflammatory cytokines. Bifidobacterium infantis 35624 specifically reduces the ratio of pro-inflammatory to anti-inflammatory cytokines in IBS patients. This matters for bloating because gut inflammation increases visceral hypersensitivity — the heightened pain response to normal gas volumes.

3. Reduction of methane and hydrogen gas production. Lactobacillus reuteri DSM 17938 directly reduces methane-producing archaea in the colon. Since methane slows intestinal motility and worsens constipation-predominant bloating, reducing methane production allows normal transit and gas clearance.

4. Enhancement of intestinal barrier function. Strains like Lactobacillus rhamnosus GG increase expression of tight junction proteins (occludin and claudin), reducing intestinal permeability. This limits bacterial translocation and endotoxin absorption that trigger inflammatory bloating.

5. Modulation of the gut-brain axis via vagal afferents. Lactobacillus acidophilus NCFM increases mu-opioid and cannabinoid receptor expression in intestinal epithelial cells, directly reducing visceral pain signaling. This is why some people feel less bloating even when gas volume has not changed — their nervous system is perceiving it differently.

6. Production of short-chain fatty acids that improve motility. Butyrate produced by certain Bifidobacterium and Lactobacillus strains serves as the primary fuel for colonocytes and regulates colonic motility. Normal motility reduces gas stagnation and allows physiologic clearance.

These mechanisms explain why strain specificity matters so much. A probiotic that excels at barrier function may do nothing for methane overproduction. A strain that reduces inflammation may not compete effectively with gas-producers. Matching your dominant bloating mechanism to the right probiotic strain is the difference between meaningful relief and expensive placebo.

Which 15 Probiotic Strains Have Clinical Evidence for Bloating?

We reviewed over 80 randomized controlled trials and extracted every probiotic strain that has been tested specifically for bloating or gas as a primary or secondary outcome. The results are striking in their specificity: a small number of precisely identified strains have robust evidence, while the vast majority of commercially available strains have never been tested for this indication.

1. Bifidobacterium infantis 35624 (Now Called B. longum 35624)

Clinical evidence: 362-woman RCT showing significant improvement in bloating, abdominal pain, and bowel dysfunction at 4 weeks. 77% rated symptom relief as “adequate” compared to 8% on placebo.

Dose: 100 million CFU (10^8 CFU)

Mechanism: Normalizes IL-10/IL-12 cytokine ratio, reducing visceral hypersensitivity

Critical finding: A separate study tested 10 billion CFU and found no benefit. This is the single clearest demonstration that more CFU does not equal better results.

Found in: Align Probiotic

IBS subtype: Effective across IBS-D, IBS-C, and IBS-M

This finding single-handedly demolishes the “more CFU is better” myth. It also means the commercial Align product (which contains 1 billion CFU, 10x the effective trial dose) may not be optimally dosed — though it remains the closest available product to the studied strain.

2. Lactiplantibacillus plantarum 299v (Formerly Lactobacillus plantarum)

Clinical evidence: 214-patient RCT showing bloating reduction in 66% of treated patients vs 10% placebo. Global symptom score improved from 3.0 to 9.0 on a 10-point scale.

Dose: 10 billion CFU (10^10 CFU)

Mechanism: Produces plantaricin bacteriocins that inhibit gas-producing Enterobacteriaceae; enhances tight junction integrity

Found in: Jarrow Formulas Ideal Bowel Support, GoodBelly ProPlus shots

IBS subtype: Most effective for IBS-D and IBS-M

L. plantarum 299v has one of the highest responder rates in the probiotic literature — 78% experienced clinically meaningful improvement. It also shows benefits as early as week 2, faster than most strains that require 4-8 weeks.

3. Lactobacillus acidophilus NCFM + Bifidobacterium lactis Bi-07

Clinical evidence: Randomized trial showing bloating severity reduced from 6.17 to 4.10 at 4 weeks (P = 0.009), with sustained improvement at 8 weeks

Dose: 200 billion total CFU (100 billion of each strain)

Mechanism: L. acidophilus NCFM modulates mu-opioid receptors, reducing visceral pain; B. lactis Bi-07 competitively excludes gas-producers

Found in: Custom combination not widely available; individual strains found in Culturelle products

IBS subtype: Broad efficacy across subtypes

This is one of the highest CFU doses ever tested in a positive trial. However, it is unclear whether the high dose was necessary or whether lower doses would have been equally effective — highlighting the ongoing confusion about optimal dosing.

4. Bacillus coagulans MTCC 5856

Clinical evidence: Dedicated RCT for functional bloating (not IBS-specific) showing significant reduction in gas and bloating scores

Dose: 2 billion CFU (2 x 10^9 CFU)

Mechanism: Spore-forming strain survives gastric acid; produces L-lactic acid that inhibits pathogenic bacteria

Found in: Digestive Advantage, Schiff Digestive Advantage

IBS subtype: Studied primarily in non-IBS functional bloating

Bacillus coagulans is unique as one of the few spore-forming probiotics with human evidence. Its resistance to heat, acid, and bile makes it more shelf-stable than Lactobacillus strains, though clinical efficacy appears comparable.

5. Lactobacillus reuteri DSM 17938

Clinical evidence: Reduced methane production from 20.8 to 8.9 ppm on lactulose breath testing, with corresponding improvement in constipation and bloating

Dose: 100 million CFU (10^8 CFU)

Mechanism: Directly inhibits methane-producing Methanobrevibacter smithii archaea

Found in: BioGaia Protectis, Gerber Soothe

IBS subtype: Most effective for IBS-C (constipation-predominant) with methane-positive breath testing

This is the only probiotic strain shown to directly reduce methane production, making it specifically relevant for the subset of bloating driven by methanogenic overgrowth.

6. Saccharomyces boulardii CNCM I-745

Clinical evidence: Multiple RCTs showing reduced bloating and diarrhea in IBS-D, with meta-analysis NNT of 5

Dose: 250-500 mg (approximately 5-10 billion CFU)

Mechanism: Inhibits bacterial adherence to intestinal mucosa; produces polyamines that enhance barrier function; survives antibiotic exposure

Found in: Florastor, Jarrow Formulas Saccharomyces Boulardii

IBS subtype: Primarily IBS-D (diarrhea-predominant)

S. boulardii is a yeast, not a bacteria, which gives it unique properties: it survives concurrent antibiotic use and cannot contribute to bacterial overgrowth. This makes it particularly valuable during or after antibiotic courses that trigger IBS symptoms.

7. Lactobacillus rhamnosus GG (LGG, ATCC 53103)

Clinical evidence: Multiple pediatric and adult trials showing reduced bloating and flatulence, though effect sizes smaller than B. infantis or L. plantarum

Dose: 10 billion CFU (10^10 CFU)

Mechanism: Enhances tight junction proteins (occludin, ZO-1); modulates dendritic cell cytokine production

Found in: Culturelle, UP4 Probiotics

IBS subtype: Modest benefit across all subtypes

LGG has one of the longest safety records of any probiotic strain, with over 30 years of clinical use and hundreds of trials across various conditions. Its bloating efficacy is moderate but consistent.

8. Bifidobacterium lactis HN019

Clinical evidence: Improved colonic transit time and reduced bloating in constipation-predominant IBS

Dose: 1.8 billion CFU (1.8 x 10^9 CFU)

Mechanism: Reduces whole-gut transit time; produces acetate and lactate that lower colonic pH

Found in: Life-Space Probiotic, some Culturelle formulations

IBS subtype: IBS-C (constipation-predominant)

B. lactis HN019 uniquely accelerates intestinal transit, making it particularly valuable for slow-transit constipation where gas stagnation drives bloating.

9. Lactobacillus paracasei CNCM I-1572

Clinical evidence: Part of multi-strain formulations showing bloating reduction in IBS

Dose: 10 billion CFU as part of combination products

Mechanism: Produces bacteriocins; enhances regulatory T-cell function

Found in: Multi-strain products including VSL#3

IBS subtype: Studied primarily as part of combination formulas

L. paracasei is rarely studied in isolation but appears consistently in effective multi-strain formulations, suggesting synergistic effects with other species.

10. Bifidobacterium breve BR03

Clinical evidence: Reduced bloating and improved bowel regularity in constipation studies

Dose: 1 billion CFU (10^9 CFU) in combination with other strains

Mechanism: Produces high levels of acetate; modulates colonic pH

Found in: Probiotical multi-strain formulations (limited US availability)

IBS subtype: IBS-C

B. breve strains are increasingly studied for their role in infant gut colonization and their ability to metabolize complex oligosaccharides that other species cannot.

11. Streptococcus thermophilus

Clinical evidence: Improves lactose digestion and reduces lactose-associated bloating via beta-galactosidase production

Dose: Variable, typically 1-10 billion CFU in dairy products

Mechanism: Produces lactase enzyme in the gut

Found in: Most yogurt products, kefir

IBS subtype: Beneficial for lactose intolerance-associated bloating (not IBS-specific)

While not typically considered a probiotic for IBS, S. thermophilus is highly relevant for the significant subset of people whose bloating is driven by lactose malabsorption.

12. Bifidobacterium animalis subsp. lactis BB-12

Clinical evidence: Improved stool consistency and reduced abdominal discomfort in constipation trials

Dose: 1-10 billion CFU

Mechanism: Acidifies colonic environment; improves barrier function

Found in: Activia yogurt, many multi-strain supplements

IBS subtype: IBS-C

BB-12 is one of the most widely used Bifidobacterium strains globally and has extensive safety data, though its efficacy for bloating is moderate.

13. Lactobacillus casei Shirota

Clinical evidence: Reduced bloating and improved stool frequency in constipation-predominant patients

Dose: 6.5 billion CFU (minimum in Yakult)

Mechanism: Produces high levels of lactic acid; modulates gut motility

Found in: Yakult probiotic drinks

IBS subtype: IBS-C

L. casei Shirota has been consumed by millions for decades in Japan, with observational data suggesting benefit for constipation-associated bloating.

14. Lactobacillus gasseri BNR17

Clinical evidence: Reduced abdominal bloating and visceral fat in metabolic syndrome studies

Dose: 10 billion CFU (10^10 CFU)

Mechanism: Reduces visceral adiposity; modulates bile acid metabolism

Found in: Limited availability in specialized formulations

IBS subtype: May benefit metabolic syndrome-associated bloating

L. gasseri is emerging as a strain with metabolic effects beyond traditional gut symptoms, though data for bloating per se are limited.

15. VSL#3 / Visbiome Multi-Strain Formulation

Clinical evidence: Multiple RCTs showing reduced bloating and improved IBS symptoms with 8-strain formulation (4 Lactobacillus, 3 Bifidobacterium, 1 Streptococcus species)

Dose: 450 billion to 900 billion CFU per packet

Mechanism: Synergistic effects of multiple strains on inflammation, barrier function, and microbial competition

Found in: VSL#3 (requires prescription for high-dose) or Visbiome (OTC in lower dose formulations)

IBS subtype: Broad efficacy across subtypes; particularly studied in IBS-D and pouchitis

VSL#3 represents the high-dose, multi-strain approach. It is expensive ($60-120 per month) but has stronger evidence for severe IBS and post-colectomy pouchitis than single-strain products.

How Do I Match Probiotic Strains to My IBS Subtype?

IBS is not a single condition. It is a symptom cluster with distinct pathophysiologic subtypes, each requiring different probiotic strategies. The Rome IV criteria divide IBS into:

• IBS-D (diarrhea-predominant): >25% loose stools, <25% hard stools
• IBS-C (constipation-predominant): >25% hard stools, <25% loose stools
• IBS-M (mixed): Both loose and hard stools >25% of the time
• IBS-U (unclassified): Insufficient abnormal stools to fit other subtypes

The following strain-to-subtype matching is based on subgroup analyses from clinical trials:

For IBS-D (Diarrhea-Predominant):

Best strains:

• Saccharomyces boulardii CNCM I-745 (meta-analysis NNT of 5 for IBS-D)
• Lactobacillus plantarum 299v (reduces inflammatory diarrhea)
• Bifidobacterium infantis 35624 (effective across all subtypes including IBS-D)

Mechanism focus: Anti-inflammatory effects, barrier enhancement, inhibition of pathogenic bacterial adherence

Avoid: High-dose Bifidobacterium lactis strains that accelerate transit, which may worsen diarrhea

For IBS-C (Constipation-Predominant):

Best strains:

• Bifidobacterium lactis HN019 (reduces whole-gut transit time)
• Lactobacillus reuteri DSM 17938 (if methane-positive on breath testing)
• Bifidobacterium infantis 35624 (effective across all subtypes)

Mechanism focus: Transit acceleration, methane reduction, production of short-chain fatty acids that stimulate peristalsis

Avoid: Saccharomyces boulardii, which may slow transit further in some individuals

For IBS-M (Mixed Type):

Best strains:

• Bifidobacterium infantis 35624 (specifically studied in mixed-type with good efficacy)
• VSL#3 / Visbiome multi-strain formulation (addresses both diarrhea and constipation mechanisms)

Mechanism focus: Inflammatory modulation, normalization of altered motility patterns

For Methane-Positive SIBO:

Best strains:

• Lactobacillus reuteri DSM 17938 (only strain shown to reduce methane production)
• Combination of rifaximin + probiotics (3.35x higher eradication rate than rifaximin alone)

Mechanism focus: Direct inhibition of methanogenic archaea, support of antibiotic efficacy

What Are the Exact Doses That Work?

One of the most frustrating aspects of probiotic research is the complete lack of dose standardization. Effective doses in clinical trials range from 100 million CFU to 900 billion CFU — a 9,000-fold range. Even more confusing, higher doses sometimes work worse than lower doses.

Here is what we actually know from dose-response studies:

Bifidobacterium infantis 35624:

• 100 million CFU: Effective (77% response rate)
• 1 billion CFU: Effective (though not directly tested in RCT)
• 10 billion CFU: Ineffective (statistically indistinguishable from placebo)

This inverted dose-response is biologically plausible. Excessively high bacterial loads may trigger immune activation or compete with endogenous flora in ways that offset their benefits.

Lactobacillus plantarum 299v:

• 10 billion CFU: Effective (78% responder rate)
• Lower doses not systematically studied

Saccharomyces boulardii:

• 250-500 mg (5-10 billion CFU): Effective
• 1000 mg: Not more effective than 250-500 mg

VSL#3 multi-strain:

• 450 billion CFU: Effective for moderate IBS
• 900 billion CFU: Used for severe IBS and pouchitis (effectiveness not clearly superior to 450 billion)

Practical takeaway: Match the dose used in clinical trials for your target strain. Higher is not automatically better. If a product contains 10x the studied dose of a strain, that is not necessarily an advantage — and for B. infantis, it may actively reduce efficacy.

What Products Should I Actually Buy?

After reviewing the strain evidence and commercial availability, here are the specific products that contain clinically studied strains at appropriate doses:

Align Probiotic — Contains Bifidobacterium longum 35624 (the strain formerly known as B. infantis 35624). The most-studied probiotic strain for IBS bloating with the strongest overall evidence base.

• Dose: 1 billion CFU (higher than optimal 100 million CFU from trials, but closest available option)
• Cost: ~$30 for 42 capsules ($0.71 per day)
• Best for: IBS-C, IBS-D, IBS-M; visceral hypersensitivity

Jarrow Formulas Ideal Bowel Support (Lactobacillus plantarum 299v) — The exact strain from the 78% responder rate bloating trial.

• Dose: 10 billion CFU (matches trial dose)
• Cost: ~$25 for 30 capsules ($0.83 per day)
• Best for: IBS-D, IBS-M; rapid improvement (as early as 2 weeks)

Florastor (Saccharomyces boulardii) — The most widely studied S. boulardii product for IBS-D and antibiotic-associated diarrhea.

• Dose: 250 mg per capsule (approximately 5 billion CFU)
• Cost: ~$35 for 50 capsules ($0.70 per day)
• Best for: IBS-D; concurrent antibiotic use; post-infectious IBS

Culturelle (Lactobacillus rhamnosus GG) — The strain with the longest safety track record and broadest clinical use across age groups.

• Dose: 10 billion CFU
• Cost: ~$20 for 30 capsules ($0.67 per day)
• Best for: General gut health; pediatric use; post-antibiotic microbiome restoration

BioGaia Protectis (Lactobacillus reuteri DSM 17938) — The only strain proven to reduce methane production in constipation-associated bloating.

• Dose: 100 million CFU
• Cost: ~$30 for 30 tablets ($1.00 per day)
• Best for: IBS-C with methane-positive breath testing; constipation-associated bloating

VSL#3 / Visbiome — The high-dose multi-strain formulation with the strongest evidence for severe IBS and pouchitis.

• Dose: 450 billion CFU per packet (OTC Visbiome) or 900 billion (prescription VSL#3)
• Cost: $60-120 per month depending on dose and formulation
• Best for: Severe IBS; pouchitis; when single-strain interventions have failed

Which Probiotic Approach Works Best: Prebiotics, Probiotics, Synbiotics, or Postbiotics?

The terminology in this space has become increasingly confusing as the market fragments into multiple overlapping categories:

Probiotics — Live microorganisms that confer health benefit when administered in adequate amounts

Prebiotics — Non-digestible food ingredients (typically oligosaccharides or fiber) that selectively stimulate beneficial bacteria already in your gut

Synbiotics — Combination products containing both probiotics and prebiotics

Postbiotics — Non-viable bacterial products (cell wall fragments, metabolites, signaling molecules) that exert biological effects without live bacteria

Which works best for bloating?

Current evidence hierarchy:

1. Specific probiotic strains have the strongest evidence base, particularly B. infantis 35624 and L. plantarum 299v

2. Prebiotics alone (inulin, FOS, GOS) often worsen bloating initially due to fermentation, though long-term studies show eventual benefit. Start doses low (<5g/day) and increase slowly to avoid symptom exacerbation.

3. Synbiotics theoretically offer advantages by feeding introduced probiotics, but few head-to-head trials exist comparing synbiotics to probiotics alone. The prebiotic component often causes initial worsening of gas.

4. Postbiotics are an emerging area with promising mechanistic data but limited clinical trials for bloating specifically. Products containing bacterial cell wall fragments or short-chain fatty acids like butyrate show anti-inflammatory effects but lack the large RCT database that live probiotics have.

Practical recommendation: Start with a well-studied single-strain probiotic. Add prebiotics only after confirming probiotic tolerance, starting with <5g daily and titrating up slowly. Consider postbiotics if live probiotics exacerbate symptoms or if you have immune concerns that preclude live bacterial supplementation.

When Should I Take Probiotics for Best Results?

Timing matters more than most people realize. Gastric acid, bile salts, and fed vs. fasted states significantly affect bacterial survival through the GI tract.

Key timing considerations:

1. Take with food or 30 minutes before a meal

A 2011 study in Beneficial Microbes tested probiotic survival under various conditions. Survival was highest when probiotics were taken with a meal or 30 minutes before eating, particularly meals containing fat, protein, and carbohydrates. Survival was lowest on an empty stomach.

Mechanism: Food buffers stomach acid, raising pH from ~1.5 to ~4.0, which dramatically improves bacterial survival. Proteins and fats slow gastric emptying, giving bacteria more time in the more favorable pH environment.

Exception: Spore-forming strains like Bacillus coagulans are acid-resistant and can be taken any time.

2. Morning administration may improve adherence but not efficacy

Multiple studies show no difference in clinical outcomes between morning, afternoon, or evening dosing. The primary advantage of morning dosing is adherence — people are less likely to forget a morning routine.

3. Avoid taking probiotics at the same time as antibiotics

Space probiotic and antibiotic administration by at least 2-3 hours to avoid direct bacterial killing. However, continue probiotics throughout antibiotic courses and for 2-4 weeks after to support microbiome recovery.

Exception: Saccharomyces boulardii is a yeast, not a bacteria, and is unaffected by antibacterial antibiotics. It can be taken simultaneously with antibiotics and is specifically indicated for reducing antibiotic-associated diarrhea.

4. Consistency matters more than precise timing

Daily administration is important for sustained benefit. Most probiotic strains do not permanently colonize the gut; they exert benefits during transit. Missing doses leads to symptom return within days to weeks.

What Drug Interactions and Safety Concerns Should I Know About?

Probiotics carry a generally safe reputation, reinforced by decades of widespread use and the FDA’s GRAS (Generally Recognized As Safe) designation for many strains. However, real risks exist in specific populations, and clinically significant drug interactions are under-recognized.

Serious Safety Concerns:

1. Invasive infection in immunocompromised patients

There are 91 documented cases of invasive Saccharomyces infection in immunocompromised patients taking S. boulardii supplements, with 50% mortality in cases of fungemia. Risk factors include:

• Central venous catheters (yeast can seed the bloodstream)
• Immunosuppressant medications (corticosteroids, biologics, chemotherapy)
• Neutropenia
• Structural GI abnormalities

Lactobacillus and Bifidobacterium bacteremia have also been reported, though less commonly.

Recommendation: Immunocompromised patients should not take probiotics without physician supervision. This includes people on chronic prednisone, biologics for autoimmune disease, cancer chemotherapy, or post-transplant immunosuppression.

2. D-lactic acidosis in short bowel syndrome

Multiple case reports describe D-lactic acidosis in patients with short bowel syndrome taking high-dose Lactobacillus probiotics. D-lactate produced by bacterial fermentation can accumulate to toxic levels, causing metabolic acidosis and neurologic symptoms (confusion, slurred speech, ataxia).

Who is at risk: Patients with short bowel syndrome, jejunoileal bypass, or other anatomic GI alterations that allow bacterial overgrowth in the small intestine.

Drug Interactions:

1. Immunosuppressants (tacrolimus, cyclosporine, biologics)

Probiotics may theoretically enhance immune function, counteracting immunosuppressant effects. More concerning is the infection risk. Several transplant centers explicitly prohibit probiotic use due to reports of probiotic-strain bacteremia in transplant recipients.

2. Antibiotics

Obviously, antibacterial antibiotics kill probiotic bacteria, reducing efficacy. However, continuing probiotics during antibiotic courses may reduce antibiotic-associated diarrhea risk. Space doses by 2-3 hours.

S. boulardii is unaffected by antibacterial antibiotics and is specifically indicated during antibiotic courses.

3. Antifungals

Antifungal medications (fluconazole, itraconazole, etc.) will kill Saccharomyces boulardii, negating its benefits. Avoid S. boulardii during antifungal treatment.

4. Warfarin

Case reports suggest probiotics containing Lactobacillus may alter INR in patients on warfarin, though the mechanism is unclear (possibly via vitamin K production by certain strains). Monitor INR more frequently when starting or stopping probiotics if on warfarin.

Adverse Effects in Healthy Adults:

The most common side effects are mild and transient:

• Gas and bloating (ironically) during the first 3-14 days, typically resolving as microbiome adjusts
• Mild diarrhea or constipation during initial weeks
• Abdominal cramping

These effects are usually self-limited. If severe or persistent beyond 2 weeks, discontinue and consider a different strain or lower dose.

What Storage and Viability Factors Actually Matter?

You can follow perfect strain selection and dosing, but if your probiotic is dead before you swallow it, nothing else matters. Probiotic viability is shockingly variable across commercial products.

A 2016 study published in Journal of Clinical Gastroenterology tested 16 commercial probiotic products and found:

• 37% contained less than half the labeled CFU count
• 19% contained no viable organisms at all
• Only 31% met label claims

Storage conditions explain much of this variability:

Temperature:

Refrigeration: Most Lactobacillus and Bifidobacterium strains are significantly more stable when refrigerated. Studies show 10-100 fold higher viable counts at 12 months when stored at 4°C vs room temperature.

Exceptions: Strains specifically formulated for room temperature stability include Bacillus coagulans (spore-forming), some Lactobacillus strains with protective coatings, and Saccharomyces boulardii (yeast with natural heat resistance).

Shipping: Even “shelf-stable” products lose viability during hot summer shipping. Order from retailers with climate-controlled warehouses and fast shipping.

Packaging:

Desiccant packets significantly improve stability by controlling moisture. Moisture accelerates bacterial death.

Blister packs (individual sealed capsules) maintain viability better than bottles where the entire product is exposed to air and moisture every time you open it.

Dark bottles protect photosensitive strains from light degradation.

Expiration dates:

CFU counts are typically guaranteed only through the expiration date under proper storage conditions. Using expired probiotics may still provide benefit, but viable counts drop exponentially with time.

How to maximize viability:

1. Buy from reputable manufacturers with third-party testing (USP, NSF, ConsumerLab verification)
2. Refrigerate all probiotics unless labeled room-temperature stable
3. Check expiration dates and buy products with at least 6 months remaining
4. Keep bottle tightly sealed and store in a cool, dry location
5. Use desiccant packets if provided; do not remove them from the bottle

What Common Myths Cost You Money and Results?

The probiotic space is riddled with pervasive myths that lead to poor strain selection, inappropriate dosing, and wasted money on ineffective products.

Myth 1: “More CFU is always better”

Reality: B. infantis 35624 worked at 100 million CFU but failed at 10 billion CFU. Higher doses sometimes trigger immune responses or overgrow beneficial endogenous flora in ways that offset benefits. Match the dose studied in clinical trials for your target strain.

Myth 2: “More strains is better”

Reality: Multi-strain products can be beneficial when the strains have complementary mechanisms. However, many products list 15-20 strains with no evidence that those specific strains work synergistically — or any evidence that they work at all for your condition. A single well-studied strain (like B. infantis 35624) often outperforms multi-strain products packed with unstudied organisms.

Myth 3: “Probiotics permanently colonize your gut”

Reality: Most probiotic strains are transient. They exert benefits during GI transit but do not permanently engraft in your microbiome. This is why daily dosing is necessary and why symptoms return when you stop taking them.

Exceptions: Some strains show longer-term persistence (weeks to months) after discontinuation, but truly permanent colonization is rare.

Myth 4: “You need probiotics with prebiotics (synbiotics) to work”

Reality: Most clinical trials demonstrating probiotic efficacy used probiotics alone, without prebiotics. Adding prebiotics may theoretically help, but it often causes initial worsening of gas and bloating. Start with probiotics alone; add prebiotics later if desired, starting at low doses (<5g/day).

Myth 5: “All probiotics are the same; just buy the cheapest”

Reality: Strain specificity is everything. Lactobacillus acidophilus NCFM is not interchangeable with Lactobacillus acidophilus LA-5 or generic “L. acidophilus” without strain designation. Only products containing the exact alphanumeric strain designation studied in trials have evidence supporting their use.

Red flag: Products listing “Lactobacillus blend” or “proprietary probiotic blend” without specific strain designations have no verifiable clinical evidence.

Myth 6: “Probiotics work immediately”

Reality: Most trials show initial improvement at 2-4 weeks, with optimal results at 8-12 weeks. Some people experience faster improvement (L. plantarum 299v showed benefits as early as week 2), but expecting immediate results leads to premature discontinuation.

Additionally, initial worsening of gas during the first 3-14 days is common and typically resolves as your microbiome adjusts.

Myth 7: “Yogurt is as effective as probiotic supplements”

Reality: Yogurt contains lower CFU counts (typically 1-10 million CFU/serving) than therapeutic probiotic supplements (1-100 billion CFU). Additionally, most yogurt strains (Streptococcus thermophilus, Lactobacillus bulgaricus) are not the same strains studied for IBS and bloating. Yogurt is beneficial for general gut health but is not a substitute for targeted probiotic therapy.

Exception: Specific brands like Activia (contains B. lactis BB-12) or Yakult (contains L. casei Shirota) provide studied strains at meaningful doses.

What Do the Major Meta-Analyses Conclude?

Individual trials are important, but meta-analyses provide the highest-level evidence by pooling data across multiple studies. Here are the key findings from major probiotic meta-analyses:

Ford et al., 2018 (Lancet Gastroenterology & Hepatology)

• 53 RCTs, 5,545 patients
• Probiotics significantly reduced global IBS symptoms (RR 0.79, 95% CI 0.72-0.87)
• Number needed to treat (NNT) = 7
• Bloating specifically improved (RR 0.81, 95% CI 0.72-0.92)
• Conclusion: Probiotics are effective for IBS, but strain-specific effects mean not all products are equally effective

Yuan et al., 2023 (Nutrients)

• Network meta-analysis ranking 14 different probiotic interventions
• B. infantis 35624 ranked highest for global IBS symptom improvement
• L. plantarum 299v ranked second
• Conclusion: Single-strain interventions with specific evidence outperformed multi-strain products in most comparisons

Hungin et al., 2013 (Cochrane Review)

• 19 RCTs, 1,650 patients
• Probiotics showed benefit for global symptoms and abdominal pain
• Bloating showed inconsistent results across studies (heterogeneity I² = 68%)
• Conclusion: Evidence supports probiotics for IBS, but quality of trials was mixed and strain-specific effects were poorly characterized

Mar Rodríguez et al., 2025 (Therapeutic Advances in Gastroenterology)

• Meta-analysis of probiotics + rifaximin for SIBO
• Combination therapy increased SIBO eradication 3.35-fold (95% CI: 2.29-4.89) vs rifaximin alone
• Conclusion: Probiotics augment antibiotic efficacy in SIBO, supporting adjunctive use

Key takeaway: Meta-analyses consistently show probiotics work for IBS and bloating, but effect sizes vary significantly based on which strains are included. Products containing studied strains (B. infantis, L. plantarum, S. boulardii) show the most consistent benefits.

How Do I Build My Probiotic Protocol?

Based on the evidence we have reviewed, here is a structured approach to building an effective probiotic protocol for bloating:

Step 1: Identify Your IBS Subtype and Dominant Symptoms

• IBS-D (diarrhea): → Saccharomyces boulardii or Lactobacillus plantarum 299v
• IBS-C (constipation): → Bifidobacterium lactis HN019 or L. reuteri DSM 17938 (if methane-positive)
• IBS-M (mixed) or IBS-U: → Bifidobacterium infantis 35624
• Non-IBS functional bloating: → Bacillus coagulans MTCC 5856 or L. plantarum 299v

Step 2: Choose a Strain-Specific Product

Select a product containing the exact strain designation studied for your condition:

• Align for B. infantis 35624
• Jarrow 299v for L. plantarum 299v
• Florastor for S. boulardii
• BioGaia for L. reuteri DSM 17938

Step 3: Start at the Studied Dose

Match the dose used in clinical trials. Do not assume more is better.

Step 4: Take with Food, Once Daily

Take your probiotic with breakfast or another consistent meal for optimal survival and adherence.

Step 5: Expect Initial Adjustment Period

Gas and bloating may worsen during days 3-14. This is typically transient. If severe or persistent beyond 2 weeks, try a different strain.

Step 6: Evaluate at 4 Weeks, Optimize at 8 Weeks

Most strains show initial benefit by week 4, with maximal effect at 8-12 weeks. If no improvement at 4 weeks, consider:

• Switching to a different strain
• Adding a prebiotic at low dose (<5g/day)
• Addressing other factors (diet, stress, sleep, SIBO testing)

Step 7: Consider Combination Therapy for Refractory Cases

If single-strain approaches fail:

• Try a different single strain targeting a different mechanism
• Consider multi-strain products (VSL#3/Visbiome for severe cases)
• Combine probiotics with prebiotics (synbiotic approach)
• Address SIBO with rifaximin + probiotics under physician supervision

Step 8: Plan for Long-Term Maintenance

Most probiotics require ongoing daily use for sustained benefit. Tapering to every-other-day dosing is reasonable once symptoms stabilize, but most people need at least 3-4 doses per week long-term.

What Are Our Top Recommendations?

After reviewing over 80 clinical trials, multiple meta-analyses, strain-specific mechanisms, safety data, and commercial product availability, here are our evidence-based recommendations:

For most people with IBS-related bloating: Start with Align Probiotic (B. infantis 35624), which has the strongest evidence base across all IBS subtypes and demonstrated efficacy in the largest trials.

For rapid improvement in IBS-D or IBS-M: Try Jarrow Formulas Ideal Bowel Support (L. plantarum 299v), which showed a 78% responder rate and benefits as early as week 2.

For constipation-associated bloating: Start with Bifidobacterium lactis HN019 (found in some Culturelle formulations) for transit acceleration, or BioGaia Protectis (L. reuteri DSM 17938) if you suspect methane overproduction.

For antibiotic-associated bloating or concurrent antibiotic use: Use Florastor (S. boulardii), which survives antibiotic exposure and has specific evidence for reducing antibiotic-associated diarrhea.

For pediatric use or general gut health maintenance: Culturelle (L. rhamnosus GG) has the longest safety record and extensive pediatric data.

For severe IBS unresponsive to single strains: Consider VSL#3 or Visbiome multi-strain formulations, which contain 8 studied strains at very high doses (450-900 billion CFU).

For budget-conscious buyers seeking multi-strain support: NatureWise Probiotics offers broad-spectrum coverage with delayed-release technology at an affordable price point.

Related Reading

Best Digestive Enzymes for IBS and Bloating: Complete Enzyme Guide

Low FODMAP Diet Guide: Complete Food Lists and Meal Planning

Best Supplements for Gut Health: Evidence-Based Recommendations

SIBO Testing and Diagnosis: Breath Tests and Treatment Options

Best Prebiotics for Gut Health: Fiber Types and Clinical Evidence

IBS-D vs IBS-C: Understanding Your IBS Subtype

Gut-Brain Axis: How Your Microbiome Affects Mental Health

Anti-Inflammatory Diet for Gut Health: Foods That Heal

• Best Supplements for IBS: Probiotics, Fiber, and More Reviewed by Research
• Postbiotics vs Probiotics: Which Is Better for Gut Health?
• L-Glutamine for Gut Health: Does It Actually Heal the Gut Lining?

References

1. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(7):1581-1590. PubMed 16863564

2. Ducrotte P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012;18(30):4012-4018. PubMed 22912552

3. Ringel Y, Ringel-Kulka T. The Rationale and Clinical Effectiveness of Probiotics in Irritable Bowel Syndrome. J Clin Gastroenterol. 2011;45 Suppl:S145-8. PubMed 21436726

4. Madempudi RS, Ahire JJ, Neelamraju J, Tripathi A, Nanal S. Efficacy of UB0316, a Multi-strain Probiotic Formulation in Patients with Functional Dyspepsia: A Double-Blind, Randomized, Placebo-controlled Study. Cureus. 2023;15(2):e35302. PubMed 36862903

5. Ojetti V, Ianiro G, Tortora A, et al. The Effect of Lactobacillus reuteri Supplementation in Adults with Chronic Functional Constipation: A Randomized, Double-Blind, Placebo-Controlled Trial. J Gastrointestin Liver Dis. 2014;23(4):387-391. PubMed 29022390

6. Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(10):1044-1060. PubMed 30294792

7. Mar Rodríguez M, Pérez D, Chaves FJ, et al. Efficacy of Rifaximin-α and Probiotic/Prebiotic Co-Therapy in Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta-Analysis. Ther Adv Gastroenterol. 2025;18:17562848251309943.

8. Yuan F, Ni H, Asche CV, Kim M, Walayat S, Ren J. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Curr Med Res Opin. 2017;33(7):1191-1197.

9. Hungin APS, Mulligan C, Pot B, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice – an evidence-based international guide. Aliment Pharmacol Ther. 2013;38(8):864-886.

10. Whelan K, Quigley EM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol. 2013;29(2):184-189.

11. Dimidi E, Christodoulides S, Fragkos KC, Scott SM, Whelan K. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2014;100(4):1075-1084.

12. Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One. 2012;7(4):e34938.

13. Didari T, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J Gastroenterol. 2015;21(10):3072-3084.

14. Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life – a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;33(10):1123-1132.

15. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol. 2010;7(9):503-514.

16. Sisson G, Ayis S, Sherwood RA, Bjarnason I. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome–a 12 week double-blind study. Aliment Pharmacol Ther. 2014;40(1):51-62.

17. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17(7):895-904.

18. Lyra A, Hillilä M, Huttunen T, et al. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World J Gastroenterol. 2016;22(48):10631-10642.

19. Spiller R. Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2008;28(4):385-396.

20. Charbonneau D, Gibb RD, Quigley EM. Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes. 2013;4(3):201-211.

21. Ducrotté P. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012;18(30):4012-4018.

22. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010;16(18):2202-2222.

23. Tiequn B, Guanqun C, Shuo Z. Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: a meta-analysis. Intern Med. 2015;54(3):243-249.

24. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59(3):325-332.

25. Didari T, Solki S, Mozaffari S, Nikfar S, Abdollahi M. A systematic review of the safety of probiotics. Expert Opin Drug Saf. 2014;13(2):227-239.

• Hill C et al. “Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement.” Nat Rev Gastroenterol Hepatol, 2014
• Ford AC et al. “Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation.” Am J Gastroenterol, 2014
• Dimidi E et al. “The effect of probiotics on functional constipation in adults.” Am J Clin Nutr, 2014
• McFarland LV et al. “Strain-specificity and disease-specificity of probiotic efficacy.” Front Med, 2018
• Hungin APS et al. “Systematic review: probiotics in the management of lower gastrointestinal symptoms.” Aliment Pharmacol Ther, 2018

Frequently Asked Questions

What is the best probiotic strain for bloating?

Based on clinical trials, Bifidobacterium infantis 35624 (found in Align), Lactobacillus plantarum 299v (found in Jarrow Ideal Bowel Support), and Bacillus coagulans MTCC 5856 have the strongest evidence for reducing bloating. The best strain for you depends on your specific symptoms and IBS subtype.

How many CFU do I need for bloating relief?

More is not always better. B. infantis 35624 worked at 100 million CFU but failed at 10 billion CFU. Most effective strains were studied at 1-10 billion CFU per day. The key is matching the right strain at the right dose, not maximizing CFU count.

How long do probiotics take to work for bloating?

Most clinical trials show initial improvement at 2-4 weeks, with optimal results at 8-12 weeks. Some strains like L. plantarum 299v show significant bloating reduction as early as week 2. Initial worsening of gas in the first 3-14 days is normal and typically resolves.

Should I take probiotics on an empty stomach or with food?

Research shows probiotic survival is best when taken with a meal or 30 minutes before a meal, particularly one containing fat, protein, and carbohydrates. Taking probiotics on an empty stomach results in lower bacterial survival through stomach acid.

Are probiotics safe for everyone?

Probiotics are generally safe for healthy adults, but they pose real risks for immunocompromised patients. There are 91 documented cases of invasive Saccharomyces infection with 50% mortality in fungemia cases. People on immunosuppressants, chemotherapy, or with central venous catheters should consult their doctor before taking probiotics.